To the best of our knowledge, this is the first study to assess changes in the level of MCP-1 chemokine after an intervention related to the use of DASH diet in patients with CAD, and the usefulness of this marker in assessing progression or regression of the atherosclerotic plaque. The gene discussed is CCL2; the disease is coronary artery disorder.